Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 3-6-Year-Old Children with Autism Spectrum Disorder: A Retrospective Cohort Study

• Huvudskapare: Hamza A. Alsayouf (Författare, medförfattare), Osama Alsarhan (Författare, medförfattare), Wael Khreisat (Författare, medförfattare), Azhar Daoud (Författare, medförfattare)
• Materialtyp: Bok
• Publicerad: MDPI AG, 2024-01-01T00:00:00Z.
• Ämnen: article
• Länkar: Connect to this object online.

Atomoxetine is indicated for the management of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 18 years. Few studies have assessed the safety and tolerability of atomoxetine in younger patients. This retrospective cohort study included 133 children aged 3-6 year...